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Abstract
Chimeric antigen receptor (CAR) T-cell therapy represents a revolutionary treatment for haematological
malignancies (i.e. B-ALL). However, the success of this type of treatment has not yet been achieved in solid tumors.
One hypothesis is that the immunosuppressive nature of the tumor microenvironment (TME) influences and affects
the efficacy of adoptive immunotherapy. Understanding the role of the TME and its interaction with CAR T-cells is
crucial to improve the potency of adoptive immunotherapy. In this review, we discuss the strategies and potential
combinatorial approaches recently developed in mouse models to enhance the efficacy of CAR T-cells, with
particular emphasis on the translational potential of these approaches.
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Background
Adoptive cell therapy (ACT) is a novel tool in the fight
against cancer. In particular T-cells engineered to express
Chimeric Antigen Receptors (CARs) have demonstrated
recent significant clinical efficacy with improvements in
patient outcomes for a number of hematological malig-
nancies [1–4]. CARs are synthetic molecules composed of
an extracellular binding domain, a transmembrane do-
main and an intracellular signaling/activation domain.
The extracellular component consists of the light and
heavy chain regions derived from an antibody to form a
single chain variable fragment (scFv), and serves to
recognize and bind specific tumor-associated antigens
(TAAs) in a MHC-independent manner. A hinge domain,
typically derived from CD8 or IgG4 molecules, connects
this module with the intracellular one. This last portion is
formed by CD3ζ segment which is responsible to trigger
T-cell activation. The first generation of CAR vectors was
designed with CD3ζ domain alone. Second and third gen-
erations added to CD3ζ one or two costimulatory domains
(CD28 and/or 4-1BB) respectively (Fig. 1). All these com-
ponents are typically inserted using γ-retroviral or
lentiviral transduction systems. Although silencing of
LTR-driven transgenes has been known to occur in other
tissues, vector silencing was not observed in one study of
human lymphocytes [5]. Interestingly, one study showed
that efficacy of CAR T cells in vivo is a function of the
density of CAR expression, and that this can have a sub-
stantial impact on antitumor efficacy and persistence of
CAR T cells both systemically and at the tumor site [6].
By combining the ability to avoid HLA restriction in anti-
gen recognition with high specificity and potent activation,
engineering these molecules to be expressed in T cells have
emerged as one of the most promising approaches for can-
cer treatment. However, attempts to recapitulate the suc-
cess achieved with CAR T-cells in B-cells malignancies for
solid tumors has been disappointing. The three main hur-
dles encountered for the application of CAR Tcell therapies
to solid tumors are (1) the identification of proper tumor
associated antigens, (2) the limited trafficking of adoptively
transferred cells to tumor sites and (3) the immunosuppres-
sive effect of tumor microenvironment. Here we will focus
on approaches to address the third problem (Fig. 2); others
have described approaches to the first two [7–13].
The complex and heterogeneous tumor microenviron-
ment plays an essential role in tumor initiation progres-
sion and therapeutic resistance. Recent studies have
highlighted the importance of innate immune activation
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for the generation of spontaneous T cell responses to
tumor-associated antigens and anti anti-tumor activity
Woo and colleagues showed that type I IFN-mediated
activation of the STING pathway of cytosolic DNA sens-
ing is one of the major players in sustaining a T cell
inflamed-tumor phenotype which represents a favorable
marker of responsiveness to immunotherapies [14]. Acti-
vation of the STING pathway contributes to activation
of Batf3 dendritic cells, which appear to be central to
anti-tumor immunity. These orchestrating dendritic cells
are recruited by chemokines to the tumor site, then mi-
grate to the secondary lymphatic organs and interact
with CD8+ T cells. After clonal expantion, the T cells
can migrate back to the tumor microenvironment and
carry out their effector functions against tumor cells
[15]. Although a thorough evaluation of innate immune
activators and an inflamed-tumor microenvironment in
the setting of CAR T-cells has yet to be investigated, the
role of the tumor microenvironment in modulating effi-
cacy of CAR-T cells is expected to be significant at the
level of effector T cell function if not antigen presenta-
tion. Furthermore, the degree of intra-tumoral expansion
and persistence that is required for clinical efficacy has
not been determined for solid tumors. In this review, we
discuss various aspects of the tumor microenvironment
that could inhibit the efficacy of immune responses, and
some of the approaches recently developed to reprogram
the tumor microenvironment in order to enhance the ef-
ficacy of CAR T-cell therapy; some of these may also
serve to enhance tumor sensitivity to other forms of im-
munotherapy. Indeed although the focus of this review
is on CAR T cells, many of the principles herein
discussed apply to and have been elucidated from studies
of adoptive cell therapy more broadly, including tumor
infiltrating lymphocytes (TILs) and TCR-engineered T
cells [16–18].
Targeting hypoxia, nutrient starvation, and
metabolism
Hypoxia and nutrient starvation are major hallmarks of the
tumor microenvironment [19]. The lack of nutrients, par-
ticularly amino acids such as tryptophan, is able to activate
the integrated stress response which regulates T-cell activity
[20]. Indoleamine 2,3 dioxygenase (IDO) is an intracellular
enzyme which catalyzes the degradation of tryptophan to
kynurenine. Both tumor cells and myeloid cells within the
tumor microenvironment can express IDO, leading to a
block in the proliferation and survival of T-cells. Recently,
Ninomiya and colleagues [21] demonstrated that IDO ex-
pression can also inhibit CAR T cells. In particular, they
showed that CD19 CAR T-cells fail to control progression
of CD19+ IDO-expressing tumors. The accumulation of
kynurenine inhibited expansion, cytotoxicity and cytokine
secretion of CAR T-cells, suggesting a plausible mechanism
underlying the resistance of IDO positive tumors to this
type of treatment. Interestingly, they demonstrated that flu-
darabine and cyclophosphamide administration improved
the efficacy of CAR T-cells by decreasing the expression of
IDO. The combination of CAR T-cells and IDO inhibitors
may represent a valuable option for malignancies resistant
to chemotherapy and immunotherapy.
Moreover it is possible that metabolic stress in the
tumor environment is able to modulate T cell metabolism,
differentiation and effector functions. Indeed, tumor
Fig. 1 CAR structure. All different generations of CAR are composed of an extracellular antigen- binding domain (usually derived from an an
antibody and engineered into an scFv), a hinge region, a transmembrane domain and various intracellular domains. First generation CARs have
CD3ζ as the only signaling domain. In second generation CARs, one costimulatory domain was added, while third generation contain both CD28
and 4-1BB costimulatory signalling domains
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infiltrating lymphocytes modify their metabolism as a re-
sponse to hypoxia, which is characteristic of solid tumors
[22]. Interestingly, it has been demonstrated that CAR T-
cells with different costimulatory domains utilize distinct
metabolic pathways, which in turn reflect variable persist-
ence within the tumor microenvironment [23]. Kawalekar
and colleagues showed that 4-1BB CAR T-cells had in-
creased mitochondrial biogenesis, which prompted a cen-
tral memory phenotype and led to a survival advantage
compared to CAR T cells with the CD28 signaling do-
main. In contrast, CD28-CAR T-cells yielded effector
memory phenotype and enhanced glycolysis. This study
highlighted the significance of the design of engineered T-
cells with regard to their survival and exhaustion in the
immunosuppressive tumor microenvironment.
Altering metabolic components within the tumor
microenvironment is only one possibility for maximiz-
ing the potential of CAR T cells. In a more recent
study Newick and colleagues [24] demonstrated simi-
lar findings by inhibiting protein kinase A (PKA) acti-
vation. PKA is the downstream effector of two other
immunosuppressive factors produced within the
tumor microenvironment: prostaglandin E2 (PGE2)
and adenosine. Different studies have reported the role
of these two molecules as potent inhibitors of T-cell
proliferation and activity [25, 26]. The authors dis-
rupted PKA anchorage to the lipid rafts by expressing
RIAD (regulatory subunit I anchoring disruptor) pep-
tide. This peptide is able to displace the association
between PKA and ezrin, a protein necessary to tether-
ing PKA close to adenylyl cyclase. Mesothelin-directed
CAR-RIAD T-cells exhibited higher infiltration, per-
sistence and antitumor activity in vivo compared to
mesothelin-directed CAR T-cells. Moreover, the ex-
pression of RIAD led to an increased chemotaxis,
guided by an induction of CXCR3 expression, and to
better adhesion. As this approach is translated to clin-
ical trials, the immunogenicity of the peptide may be-
come an issue.
Another way to reprogram the tumor microenviron-
ment is to augment the antitumor response of CAR T-
cells by facilitating the recruitment of an endogenous
Fig. 2 Targeting different components of the tumor microenvironment to enhance the efficacy of CAR T-cell therapy. Efforts to overcome the inhibitory ef-
fect of TME include strategies that target immunosuppressive populations (i.e. PGE2), stroma cells, cytokine networks and immune checkpoint signals
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immune response. This approach was validated by
Curran and colleagues [27] through the constitutive
expression of CD40L by CAR T-cells. They demon-
strated that this strategy improves CAR T-cell cytotox-
icity, decreases expression of PD-1, and improves DC
antigen presentation function in a systemic model of
CD40 positive follicular lymphoma. These mecha-
nisms are likely to be synergistic with the STING
pathways described by Gajewski and colleagues (as
above).
Thus targeting tumor immunosuppressive populations
such as PGE2 and/or T-cells response to the altered
microenvironment represents an exciting opportunity to
increase the efficacy of immunotherapy.
Targeting stroma
Enhancing the efficacy of anti-tumor immune therapies
could also be accomplished by targeting the non-
malignant cancer-associated stromal cells (CASCs). These
cells secrete growth factors, cytokines, and chemokines
that promote tumor growth, metastasis and angiogenesis.
One attractive stromal candidate is the fibroblast activa-
tion protein (FAP), a serine protease implicated in extra-
cellular matrix remodeling and selectively expressed by
CASCs in over 90% of epithelial cancers [28]. Three differ-
ent groups have described the use of anti-FAP CAR T-
cells with some contrasting results. Tran and colleagues
[29] showed that despite anti-FAP CARs displaying spe-
cific degranulation and production of effector cytokines in
response to antigen stimulation in vitro, they didn’t medi-
ate an efficient antitumor response in vivo, and unexpect-
edly and alarmingly, anti-FAP CARs caused severe
cachexia and lethal bone toxicities. The authors found that
FAP protein is also expressed by multipotent bone mar-
row stromal cells (BMSCs) and related the observed tox-
icity to this expression. However, Kakarla and colleagues
[30] using a FAP-CAR with a different scFv demonstrated
antitumor efficacy without toxicities in a mouse model of
human lung cancer. Even if T-cell persistence was limited,
an improved response was achieved by co-injecting FAP-
specific and tumor-specific T-cells. Schuberth and col-
leagues [31] developed an intra-peritoneal model for the
adoptive transfer of FAP-CARs in a mesothelioma xeno-
graft. Their data showed an increased survival; however,
their anti-human FAP scFv did not have cross-reactivity
with mouse FAP, which limited their ability to evaluate the
on-target/off-tumor toxicity. A paper by Wang and col-
leagues [32] suggested that targeting FAP positive cells en-
hanced antitumor immunity via epitope spreading. They
showed activation of endogenous CD4+ T-cells after three
days of anti-FAP CAR treatment in an immune-
competent syngeneic mouse model of mesothelioma and
lung cancer. CD4+ activation was followed by a later aug-
mentation of endogenous CD69+, INFγ +CD8+ T-cell
infiltration. This antitumor response did not occur in im-
munodeficient mice, supporting the importance of the
adaptive immune system. In another publication, the same
group underlined the relevance of FAP inhibition by
showing it also had an immune-independent antitumor
effect. Using a weakly immunogenic and highly desmo-
plastic tumor, pancreatic ductal adenocarcinoma, Lo and
colleagues [33] demonstrated that FAP-CAR T-cells inhib-
ited tumor stromagenesis, reduced tumor vascular density
and disrupted spatial orientation of tumor cells.
The safety concerns generated by the work of Rosenberg
et al. [29] may be related to the specificity and affinity of
the scFv, given that the last two studies with CAR T cells
with different scFvs that recognize highly positive FAP cells,
have been reassuring. Given the potential for multi-modal
anti-tumor effects of FAP targeting, rational and interesting
combinations for future immunotherapeutic approaches in-
clude anti-stroma CAR T-cells with either anti-tumor CAR
T-cells or checkpoint blockade.
Beyond targeting FAP, another recent strategy for
using CAR T cells in stroma-rich tumors is to target the
enzyme heparanase (HPSE). This enzyme is responsible
of the degradation of the heparan sulfate proteoglycans
(HPGs), a fundamental process for the trafficking and
accumulation of T-cells to the tumor site. Caruana and
colleagues [34] demonstrated that CAR T-cells lose the
expression of HSPE during their manufacturing process.
This phenomenon leads to an impaired ability to de-
grade the extracellular matrix, suggesting a compromise
in migration capacity. The authors showed that the in-
duction of HSPE expression enhanced tumor infiltration
and improved survival in neuroblastoma xenograft
models.
Targeting cytokine networks
Another potential option for shaping the tumor micro-
environment to enhance ACT efficacy is to induce the local
release of stimulatory factors that promote anti-tumor im-
mune responses. In this context interleukin-12 (IL-12) and
IL-18 represent promising candidates. In particular, IL-12 is
an inflammatory cytokine, able to improve T-cell activation
and induce a Th1 CD4+ T-cell response, CD8+ clonal ex-
pansion, and effector function. It is also able to recruit NK
cells to the tumor site, reactivate anergic tumor-infiltrating
lymphocytes (TILs), inhibit regulatory T-cells and the se-
cretion of IL-10, IL-4 and trasforming growth factor beta
(TGFβ) by tumor associated macrophages [35–39]. Starting
from these considerations, several groups devised the
“fourth generation” CAR T-cells combining IL-12 secretion
with CAR expression. Koneru and colleagues [40] used the
so called T-cells redirected for universal cytokine-mediated
killing (TRUCK) to treat an orthotropic ovarian tumorgraft
model. They showed complete eradication of tumor, pro-
longed persistence of CAR T-cells and higher systemic
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IFNγ levels. In order to increase the safety and reduce un-
desired toxicities that could be generated by constitutive,
systemic high levels of IL-12, which have been toxic in clin-
ical trials [41], they developed a tricistronic vector that en-
codes the scFv specific for MUC-16ecto antigen, IL-12 and
the truncated EGFR elimination gene (EGFRt) and admin-
istered it locally. Peritoneal administration of CAR T-cells
was significantly more effective compared with intra-
venous administration. This paper paved the way for a
phase I clinical trial in platinum-resistant ovarian cancer
patients, which will determine the safety and feasibility of
this approach [42]. The production and release of a trans-
genic payload in a CAR should minimize toxicities in
addition the “switch-off” system such as the EGFRt pro-
vides an additional measure of control for safety.
Furthermore IL-12 expression has proved to be im-
portant for the generation and efficacy of CAR T-cells
from the umbilical cord blood (UCB). Pegram and col-
leagues [43] described a novel technique to expand and
genetically modify UCB T-cells. First, they demonstrated
that adding IL-12 and IL-15 to the cultured activated
UCB T-cells led to a 150-fold expansion of this popula-
tion, which showed an ideal phenotype expressing both
memory and effector markers. Second, including the ex-
pression of IL-12 in the anti-CD19 CAR vector resulted
in a significant increase in survival of mice bearing acute
lymphoblastic leukemia (ALL), without the need for pre-
treatment or Il-2 support. These data support the clin-
ical translation of using ACT to further boost the graft-
versus-leukemia effect in UCB-transplanted patients
with high-risk, relapsed/refractory ALL.
Another feasibile strategy to modulate tumor microenvir-
onment signalling is to directly inhibit TGFβ, IL-10, and/or
IL-4 signaling. The secretion of the first molecule by cancer
cells and cancer associated cells is a well know mechanism
of tumor evasion, and IL-10 as well as IL-4 are potent im-
munosuppressive cytokines. One approach is to force the
overexpression of a dominant negative form of the receptor
on T cells. Zhang and colleagues [44] demonstrated an in-
creased antitumor efficacy in vitro and in vivo of T cells
overexpressing TGFβ DNRII in a melanoma tumor model.
Despite the promising results, further studies have to be
done in orther to validate this approach in the context of
CAR T-cell therapy. An additional recent system developed
by Mohammed and colleagues [45] for the treatment of
prostate cancer, a tumor characterized by elevated IL-4
levels, consists in an inverted cytokine receptor (ICR). Spe-
cifically, this 4/7 ICR is formed by the extracellular domain
of the inhibitory IL-4 receptor linked to the intracellular
immunostimulatory domain of IL-7. The co-expression of
anti-PSCA first generation CAR vector and ICR resulted in
an increased in vitro and in vivo antitumor activity. This
approach transforms an inhibitory signal for T cells into a
stimulatory one and at the same time deprives cancer cells
of an important growth factor. The combination of a sec-
ond generation CAR with 4/7 ICR could be evaluated to
improve on these results.
Targeting immune checkpoints
A major mechanism through which the tumor-
microenvironment exerts its immune-inhibition is indu-
cing the upregulation of surface inhibitory receptors such
as cytotoxic T-lymphocyte-associate protein 4 (CTLA-4)
and programmed death-1 (PD-1). These molecules are
naturally upregulated after antigen-receptor engagement
to dampen T-cell activation within tissues and maintain
peripheral tolerance. A better understanding of the activa-
tion of these intrinsic inhibitory pathways by the tumor-
microenvironment led to the success of immune check-
point therapies [46]. Furthermore recent studies have un-
covered the critical role of PD-1 in human CAR T-cell
exhaustion. John and colleagues [47] published the first
proof-of-concept study that CAR T-cells express PD-1
and are susceptible to PD-1 mediated suppression. The
authors showed an improvement in antitumor activity
when Her2+ tumor-bearing mice were treated with a
combination of CAR T-cells and anti PD-1 antibody.
Interestingly, the marked tumor regression was accom-
panied by a decrease of myeloid-derived suppressor cells
(MDSC) in the tumor microenvironment. However, the
mechanism of increased antitumor activity and role of the
modulation of the MDSCs remain to be proven. A later
study by Moon and colleagues [48] confirmed an aug-
mented expression of PD-1 on CAR TILs which corre-
lated with their hypofunction in a mesothelioma model.
By blocking PD-1, they restored mesothelin-directed CAR
T cell cytotoxicity in vitro. Beyond administering immune
checkpoint antibodies, an alternative way of blocking im-
mune checkpoints is to use genetic engineering strategies.
For example, Liu and colleagues [49] inserted the
PD1:CD28 switch-receptor into CAR vectors. This recep-
tor was developed by Prosser et al [50] and it is engineered
to express the extracellular domain of PD1 fused to the
transmembrane and signaling domains of CD28; this con-
struct could function as a dominant negative by compet-
ing with endogenous PD1 and/or could actively signal
through the cytoplasmic domain after PD-L1 binding. The
authors performed an analysis of effector functions of
PD1:CD28 CAR T-cells injected intravenously to treat
large, established, solid tumor including mesothelioma
and prostate cancer in xenograft models. They reported a
significant increase of the frequency of CAR TILs both in
tumors and in peripheral blood, a greater ex vivo antitu-
mor function, and more cytokine secretion. Of interest,
the employment of a switch-receptor with a mutant sig-
naling domain abrogated these results, suggesting a cen-
tral role for the CD28 costimulatory domain in the fusion
construct. Conversely, Cherkassky et al [51] demonstrated
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that combining CAR T-cells with the expression of a
“dominant negative” form of PD-1 led to higher persist-
ence, increased antitumor effects and prolonged survival
in a mesothelioma xenograft model. The “dominant nega-
tive” form of PD1 in this model was composed of the only
the extracellular domain of PD1 (without a signaling do-
main), which would presumably compete with endogen-
ous PD1 for ligating PD-L1. One explanation for these
divergent results could be the different type of tumor
treated. Moreover, Cherkassky and colleagues showed that
CAR T-cells with 4-IBB costimulatory domain were able
to function at lower doses compared to CAR T cells that
included CD28 signaling domains, and 4-1BB-signaling
CARs were more resistant to PD-1 mediated exhaustion.
Additional tumor models are necessary to show that
PD-1-mediated CAR T-cell suppression is a general in-
hibitory mechanism, particularly immunocompetent
mouse models. It will be also important to understand
the role of the costimulatory domains embedded into
CARs and their differential mechanisms in mediating re-
sistance to inhibitory molecules and inducers of CAR T-
cell exhaustion. Even if the safest and most efficacius
checkpoint combinations have yet to be identified [52],
altogether these pre-clinical data provide supportive evi-
dence that combining immune checkpoint blockade with
CAR T-cells is a logical therapeutic strategy to improve
the clinical outcome of CAR T-cell therapy in patients.
Conclusions
Adoptive cell therapy using CAR T-cells has demon-
strated impressive therapeutic potential for the treat-
ment of certain B cell malignancies. Even though there
have been recent exciting publications using TIL therapy
targeting mutant KRAS metastatic colorectal cancer [53]
and IL13Rα2-targeted CAR T cells in glioblastoma mul-
tiforme [54], results in solid malignancies may be subject
to various limitations, including the immunosuppressive
tumor microenvironment. Indeed, the microenviron-
ment non only creates a physical barrier decreasing the
penetration of modified T-cells into the tumor mass, but
also plays an active role in immune suppression through
the up regulation of inhibitory signals. Innovative strat-
egies have been developed to overcome these challenges
(Fig. 2), including co-administration of CAR T cells with
checkpoint blockade, and co-administration with other
drugs, therapies, and CAR T cells that target the tumor
stroma and immunosuppressive molecules. Many of
these strategies have been tested in xenograft and syn-
geneic mouse models, and clinical trials of these combi-
nations are warranted and eagerly awaited. Pre-clinical
experiments will define rational combinations of these
approaches, based on a deeper understanding of the
unique tumor characteristics and interplay among im-
mune cells and the tumor environment. Translating the
optimal combinations is likely to require iterative clinical
trials to determine the safest and most effective combi-
nations for patients with solid tumors.
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